BEIJING, July 23, 2014 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, announced today
that it has been selected by the Beijing Centers for Disease
Control and Prevention ("Beijing CDC") to be a supplier of the
seasonal influenza vaccine to the citizens of Beijing for 2014.
The Beijing CDC plans to order a minimum of 1.2 million doses of
the seasonal flu vaccine this year from four domestic vaccine
manufacturers for its vaccination campaign. Each manufacturer has
agreed to supply no less than 300,000 doses. If required by the
government, Sinovac may deliver additional vaccines. The exact
quantity of doses to be ordered will depend on demand during the
flu season. In 2013, Sinovac supplied approximately 400,000 doses
of Anflu for the influenza vaccination campaign in Beijing. During last year's campaign, the
Beijing CDC administered a total of approximately 1.49 million
doses for free to its target population. The Company expects to
begin delivering the vaccines in the third quarter of 2014.
Mr. Weidong Yin, Chairman,
President and CEO of Sinovac, commented, "We are pleased to be
selected once again by the CDC to supply seasonal flu vaccines for
Beijing citizens. This vaccination
campaign is an important step in protecting geriatric and
school-age populations from influenza."
The Beijing CDC began purchasing seasonal flu vaccines in 2007
to prevent and control the spread of influenza among populations
most susceptible to complications from the virus. Each year, the
Beijing CDC evaluates potential suppliers on product quality,
service and price, among other factors.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases including hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps, as well as animal rabies vaccine for canines. The Company
filed a new drug application for enterovirus 71 (against hand, foot
and mouth disease) with China Food & Drug Administration. In
2009, Sinovac was the first company worldwide to receive approval
for its H1N1 influenza vaccine, Panflu.1, and has manufactured it
for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only
supplier of the H5N1 pandemic influenza vaccine to the
government-stockpiling program. Sinovac is developing a number of
new pipeline vaccines including vaccines for pneumococcal
polysaccharides, pneumococcal conjugate, varicella, and sIPV.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the
Philippines. Sinovac has also been granted a license to
commercialize seasonal flu vaccine in Mexico and hepatitis A vaccine in Chile.
Contact
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
SOURCE Sinovac Biotech Ltd.